Difference between revisions of "Nedaplatin (Aqupla)"
m |
m |
||
| Line 14: | Line 14: | ||
*'''Generic name:''' nedaplat | *'''Generic name:''' nedaplat | ||
*'''Brand name:''' Aqupla, Jiebaishu | *'''Brand name:''' Aqupla, Jiebaishu | ||
| − | |||
| − | |||
==References== | ==References== | ||
<references /> | <references /> | ||
| Line 29: | Line 27: | ||
[[Category:Non-small cell lung cancer, squamous medications]] | [[Category:Non-small cell lung cancer, squamous medications]] | ||
[[Category:PMDA approved drugs]] | [[Category:PMDA approved drugs]] | ||
| − | |||
Revision as of 14:15, 11 February 2023
General information
Class/mechanism: A second-generation cisplatin analogue with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. [1]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
- Cervical cancer
- Nasopharyngeal carcinoma
- Non-small cell lung cancer, squamous
- Non-small cell lung cancer, EGFR-mutated
Also known as
- Code name: 254-S
- Generic name: nedaplat
- Brand name: Aqupla, Jiebaishu
References
[[